OUR PURPOSE

Influenza can kill.

**We believe** it shouldn’t be that way.

**We exist to** transform influenza protection.
INCREASING IMMUNIZATION RATES AND IMPROVING VACCINE EFFECTIVENESS UNITES ALL OF US IN THE FIGHT AGAINST INFLUENZA

WHILE VACCINATION REMAINS THE BEST PROTECTION AGAINST INFLUENZA, VARYING VACCINE EFFECTIVENESS ERODES PUBLIC CONFIDENCE

References:
SEQIRUS supports the WHO’s efforts to improve vaccine effectiveness through increased data analysis.

How do we optimize H3N2 manufacturing yields and gain access to reagents in a shorter window of time?

How do we mitigate vaccine supply bottlenecks?

How do we collaborate to ensure Immunization Campaigns aren’t negatively impacted?

Supply Update: Seqirus plans to supply 50+ million doses across 3 brands

<table>
<thead>
<tr>
<th>AGE</th>
<th>DESCRIPTION</th>
<th>PRESENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>65+ years</td>
<td>Egg-based inactivated trivalent influenza vaccine adjuvanted with MF59®</td>
<td>PFS</td>
</tr>
<tr>
<td>4+ years</td>
<td>Cell-based inactivated quadrivalent influenza vaccine</td>
<td>PFS, MDV</td>
</tr>
<tr>
<td>6+ months</td>
<td>Egg-based inactivated quadrivalent influenza vaccine</td>
<td>PFS, MDV</td>
</tr>
</tbody>
</table>

Abbreviations: PFS, prefilled syringe; MDV, multidose vial.
Note: The PFS presentation is preservative free.
WE ALL HAVE A ROLE IN CHANGING THE PARADIGM...

New Technologies
Strain Selection
Advocacy & Policy
Research & Development

Disease Surveillance
Education & Best Practice Sharing
Robust Manufacturing
Real World Evidence

INNOVATIVE TECHNOLOGIES

TECHNOLOGIES TO ADDRESS THE UNIQUE CHALLENGES OF THE INFLUENZA VIRUS

Cell-Based
Adjuvant
ROBUST MANUFACTURING

SEQIRUS HAS A ROBUST NETWORK WITH A SOLE FOCUS ON INFLUENZA VACCINE MANUFACTURING

Liverpool, UK
- One of the largest biotechnology sites in Europe
- The only injectable influenza vaccine facility in the UK
- The only licensed adjuvanted seasonal influenza vaccine is produced here
- Bulk vaccine manufacturing with fill/finish capabilities

Holly Springs, North Carolina, USA
- State-of-the-art facility that uses an advanced cell-based manufacturing process, offering an alternative to conventional seasonal influenza vaccines
- Result of a joint partnership with the US Biomedical Advanced Research and Development Authority to enhance pandemic preparedness

Parkville, Melbourne, Australia
- Producing influenza vaccines for 8 decades
- Egg-based manufacturing

IMMUNIZATION & BUSINESS SOLUTIONS

PARTNERING WITH CUSTOMERS TO PROVIDE CUSTOMIZED SOLUTIONS & SUPPORT

Clinical
Financial
Operational
REAL WORLD EVIDENCE

AN EVOLVING TOOL TO INFORM INFLUENZA VACCINES DECISION MAKING

Healthcare Providers
Vaccine Manufacturers
Clinical Researchers
Policy Makers & Regulators